TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
October 13, 2015 at 07:00 AM EDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company has completed patient ...
